- Reframe Daily
- Posts
- Reframe Daily: Start sotatercept early, acupuncture eases post-surgery leaks, needle-free flu boost
Reframe Daily: Start sotatercept early, acupuncture eases post-surgery leaks, needle-free flu boost
Early sotatercept helps people with PAH now; a clinic electroacupuncture protocol cut urine symptoms after prostate surgery; a nose-spray flu booster and an RNA replicon COVID-19 vaccine showed strong protection in early tests; and a new fusion protein made cancer-fighting T cells hit harder.
Christin Chong, PhD
September 30, 2025
Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.
Today in one sentence: Starting sotatercept soon after diagnosis helped people with lung blood-pressure disease; a randomized trial found electroacupuncture eased urine problems after prostate surgery; a nose-spray flu booster protected well in animals; a new RNA-replicon COVID-19 vaccine platform looked safe and strong in early tests; and a smart fusion protein made cancer-fighting T cells work longer.
Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8
Weekly personal shares from Christin here →
http://christin.substack.com/
Good news: A proven PAH drug helped people even when started early after diagnosis, which could keep lungs and heart healthier sooner.
Market readiness: 😀😀😀😀😀 (already FDA-approved in the US for PAH; this trial extends evidence to early treatment, so people can benefit now).
Good news: A simple clinic procedure (electroacupuncture) eased urine problems after prostate surgery in a randomized trial.
Market readiness: 😀😀😀😀 (procedure is available in many US clinics; protocol needs adoption/replication before it’s standard care).
Good news: A needle-free booster given through the nose sparked strong flu protection in preclinical work—pointing to easier, broader immunity.
Market readiness: 😀😀 (compelling preclinical data; human trials still needed).
Good news: A next-gen RNA “replicon” vaccine platform for COVID-19 showed safety and strong responses in lab/animal studies, a step toward longer-lasting vaccines.
Market readiness: 😀😀 (preclinical platform; requires human trials and regulation).
Good news: Engineers designed a fusion protein to supercharge cancer-fighting T cells by reshaping immune signals—promising a stronger, longer attack on tumors.
Market readiness: 😀😀 (innovative, but still preclinical; needs human testing).
Thank you for taking the time to take care of yourself and your loved ones.